NCT05407389View on ClinicalTrials.gov

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

PHASE2/PHASE3SuspendedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Chronic Kidney Disease stage4
Interventions
DRUG

KT-301 (formerly US-APR2020)

KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).

Trial Locations (5)

20904

Jadedstone Clinical Research, Silver Spring

22192

Mendez Center for Clinical Research, Woodbridge

29118

South Carolina Clinical Research, Orangeburg

48604

Kidney Michigan, Saginaw

77058

Almeda Medical Clinic, Houston

Sponsors

Lead Sponsor

Kibow Pharma
All Listed Sponsors
lead

Kibow Pharma

INDUSTRY